IDEAYA Biosciences (IDYA) Cash & Equivalents (2018 - 2026)

IDEAYA Biosciences has reported Cash & Equivalents for 9 years, with the latest figure at $157.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 59.86% year-over-year to $157.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.5 million (up 59.86% YoY) and the FY2025 annual result came in at $112.8 million, up 33.71% from the prior year.
• Cash & Equivalents grew to $157.5 million in Q1 2026 per IDYA's latest filing, from $112.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $400.3 million in Q3 2024 and troughed at $49.1 million in Q2 2022.
• A 5-year average of $136.0 million and a median of $108.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 59.57% in 2022, then jumped 163.6% in 2024.
• Over 5 years, Cash & Equivalents stood at $68.6 million in 2022, then soared by 128.78% to $157.0 million in 2023, then sank by 46.26% to $84.4 million in 2024, then surged by 33.71% to $112.8 million in 2025, then jumped by 39.62% to $157.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $157.5 million, $112.8 million, and $298.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.